Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Flupentixol/Melitracen Formulations
NCT02179931Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of flupentixol + melitracen in anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by Lundbeck. Primary endpoints: Area under the flupentixol plasma concentration-time curve from zero to 72 hours post dose, Maximum observed concentration of flupentixol and 2 more. Started Jun 2014; status: completed.
02
Drugs
flupentixol + melitracen
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02179931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179931.